Shantha Biologics has teamed up with Novo Nordisk to make cartridges for injectable meds at its Hyderabad plant. Big move for drug production like insulin. It involves the crucial fill-finish process, prepping cartridges for patients.
No word on financials or production numbers yet . But Shantha Biologics stressed the importance of this collaboration. Director Vishy Chebrol said Novo Nordisk picking them as a CDMO partner shows trust in their quality,technical skills. He pointed out this partnership highlights India's role in advanced manufacturing,not just low-cost output.
Cartridge fill-finish is tricky business . Ensures drugs go into pre-filled cartridges patients use with pen injectors . Keeps things sterile,doses precise. Vital for conditions like diabetes,obesity,even cancer treatments.
Founded in 1993 by Varaprasad Reddy,Shantha Biologics has changed a lot. Especially since a group led by Ravi Penmetsa and Chebrol took over in 2024. Reddy's now board chairman. The company splits into two main parts: its original vaccine line and new cartridge unit,meeting growing demand for injectables like GLP-1 therapies,antibody treatments .
Biologic drugs,from living cells,booming. In 2025,market was $25.32 billion. Expected to hit $38.29 billion by 2031. Shantha Biologics plans to boost its vaccine,biologic,injectable production.
Looking ahead,company expects to up its workforce at Hyderabad site,aiming for around 500 staff soon. Ties into the rising need for advanced pharma manufacturing solutions…
